IP Library › Granted Patent US 12692235

Granted Patent B2

US 12692235 · App. 17/790,500 · Granted Jul 28, 2026

Fused ring compound and application thereof

Inventors: Jun Lou (Wuhan, CN); Yongkai Chen (Wuhan, CN); Yihan Zhang (Wuhan, CN); Xiaodan Guo (Wuhan, CN); Lina Qian (Wuhan, CN); Li Liu (Wuhan, CN); Wei Peng (Wuhan, CN); Fei Rong (Wuhan, CN); Chaodong Wang (Wuhan, CN)

Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.

C07D217/26 C07D237/28 C07D239/72 C07D401/04 C07D401/12

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12692235
App. No.: 17/790,500
Granted: Jul 28, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

Claims (399)

1 . A fused ring compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof;

wherein,

is a single bond or a double bond;

is benzene ring, 6-membered heteroaromatic ring having one or two heteroatoms N or 6-membered heterocycloalkene having one heteroatom N;

is benzene ring;

R 1 is

R 1-1 is halogen, hydroxyl, amino, —NHR 1-1-4 , —N(R 1-1-5 )(R 1-1-6 ), C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyl substituted by one or more R 1-1-1 , C 3 -C 6 cycloalkyl substituted by one or more R 1-1-2 , or, “4- to 7-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 1-1-3 ;

R 1-1-1 , R 1-1-2 , R 1-1-3 , R 1-1-4 , R 1-1-5 and R 1-1-6 are independently halogen, hydroxyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy or “4- to 7-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”;

R 3 is

n is 0, 1, 2 or 3;

R 3-1 is independently halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyl substituted by one or more R 3-1-1 , C 1 -C 6 alkoxy substituted by one or more R 3-1-2 , or C 1 -C 6 alkoxy substituted by C 1 -C 6 alkoxy; R 3-1-1 and R 3-1-2 are independently halogen;

R 3-2 is C 3 -C 6 cycloalkyl substituted by one or more R 3-2-1 , “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 3-2-2 , “7- to 8-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 3-2-2 or “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 3-2-3 ;

R 3-2-1 , R 3-2-2 and R 3-2-3 are independently halogen, hydroxyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, or, C 1 -C 6 alkoxy substituted by C 1 -C 6 alkoxy;

m is 0, 1, 2, 3 or 4;

R 2 is oxo, halogen, cyano, isocyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 2 -C 10 alkenyl, C 2 -C 10 alkenyl substituted one or more R 2-26 , C 2 -C 10 alkynyl, C 2 -C 10 alkynyl substituted by one or more R 2-27 , C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl substituted by one or more R 2-3 , “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “3- to 4-membered heterocycloalkyl with 1 or 2 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-4 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-5 , —(C═O)—R 2-2 , —OR 2-6 , —C(═O)OR 2-7 , —NR 2-8 R 2-9 , “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 , “3- to 4-membered heterocycloalkyl with 1 or 2 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 , —C(═O)NHR 2-11 , —C(═O)NR 2-12 R 2-13 , —NR 2 - 14 C(═O)R 2-1 , —NR 2-16 S(═O) 2 R 2-17 , —NR 2-18 S(═O)R 2-19 , —S(═O) 2 NHR 2-20 , —S(═O)NHR 2-21 , —S(═O) 2 NR 2-22 R 2-23 , —S(═O) 2 R 2-24 or —S(═O)R 2-25 ;

R 2-1 is independently halogen, hydroxyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl substituted by one or more R 2-1-8 , “4- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-17 , phenyl, phenyl substituted by one or more R 2-1-1 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-1-6 , —OR 2-1-2 , —N(R 2-1-3 )(R 2-1-4 ), or, —S(═O) 2 R 2-1-5 ;

R 2-1-1 , R 2-1-6 , R 2-1-7 and R 2-1-8 are independently oxo, hydroxyl, amino, carboxyl, halogen, —CN, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more halogen, —OR 2-1-1 , or, —N(R 2-1-1-2 )(R 2-1-1-3 ); R 2-1-1-1 , R 2-1-1-2 and R 2-1-1-3 are independently C 1 -C 6 alkyl;

R 2-1-2 is independently C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-1-3 and R 2-1-4 are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-1-5 is independently C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-3 is independently C 1 -C 6 alkyl;

R 2-4 and R 2-5 are independently halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more R 2-4-3 , —N(R 2-4-1 )(R 2-4-2 ) or C 1 -C 6 alkoxy; R 2-4-1 and R 2-4-2 are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; R 2-4-3 is halogen;

R 2-2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl, C 1 -C 6 alkyl substituted by one or more R 2-2 -2, or, phenyl substituted by one or more R 2-2-1 ; R 2-2-1 is independently halogen; R 2-2-2 is independently halogen;

R 2-6 is hydrogen, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-6-1 , C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, C 6 -C 10 aryl substituted by one or more R 2-6-2 , “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” or, “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-6-3 ;

R 2-6-1 is independently oxo, halogen, hydroxyl, amino, carboxyl, —CN, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more halogen, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 , —OR 2-6-1-2 or —N(R 2-6-1-3 )(R 2-6-1-4 );

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

R 2-6-1-1 is independently halogen;

R 2-6-1-2 , R 2-6-1-3 and R 2-6-1-4 are independently C 1 -C 6 alkyl;

R 2-7 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or phenyl;

R 2-8 and R 2-9 are independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, or C 6 -C 10 aryl substituted by one or more R 2-8-1 ;

R 2-8-1 is halogen or C 1 -C 6 alkoxy;

R 2-10 is independently C 1 -C 6 alkyl or oxo;

R 2-26 and R 2-27 are independently halogen or C 1 -C 6 alkyl;

R 2-11 , R 2-12 , R 2-13 , R 2-14 , R 2-15 , R 2-16 , R 2-17 , R 2-18 , R 2-19 , R 2-20 , R 2-21 , R 2-22 , R 2-23 , R 2-24 and R 2-2 are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-11-1 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, or “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-11-2 ;

R 2-11-1 and R 2-11-2 are independently halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy or C 3 -C 6 cycloalkyl;

R 2 is located on

2 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 1 , wherein,

is a single bond or a double bond;

is benzene ring 6-membered heteroaromatic ring having one or two heteroatoms N or 6-membered heterocycloalkene having one heteroatom N;

is benzene ring;

R 1 is

R 1-1 is halogen, hydroxyl, amino, —NHR 1-1-4 , —N(R 1-1-5 )(R 1-1-6 ), C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyl substituted by one or more R 1-1 , C 3 -C 6 cycloalkyl substituted by one or more R 1-1-2 or, “4- to 7-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 1-1-3 ;

R 3 is

n is 0, 1, 2 or 3;

R 3-1 is independently halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, or, C 1 -C 6 alkoxy substituted by C 1 -C 6 alkoxy;

R 3-2-1 , R 3-2-2 and R 3-2-3 are independently halogen, hydroxyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, or, C 1 -C 6 alkoxy substituted by C 1 -C 6 alkoxy;

m is 0, 1, 2, 3 or 4;

R 2 is oxo, halogen, cyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2 -, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl substituted by one or more R 2-3 , “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-4 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-5 , —(C═O)—R 2-2 , —OR 2-6 , —C(═O)OR 2-7 , —NR 2-8 R 2-9 , “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 , —C(═O)NHR 2-11 , —C(═O)NR 2-12 R 2-13 , —NR 2-14 C(═O)R 2-1 , —NR 2-16 S(═O) 2 R 2-17 , —NR 2-18 S(═O)R 2-19 , —S(═O) 2 NHR 2-20 , —S(═O)NHR 2-21 , —S(═O) 2 NR 2-22 R 2-23 , —S(═O) 2 R 2-24 or —S(═O)R 2-25 ;

R 2-1-1 , R 2-1-6 , R 2-1-7 and R 2-1-8 are independently oxo, hydroxyl, amino, carboxyl, halogen, —CN, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more halogen, —OR 2-1-1-1 , or, —N(R 2-1-1-2 )(R 2-1-1-3 ); R 2-1-1-1 , R 2-1-1-2 and R 2-1-1-3 are independently C 1 -C 6 alkyl;

R 2-1-2 is independently C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-1-3 and R 2-1-4 are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-1-5 is independently C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-3 is independently C 1 -C 6 alkyl;

R 2-4 and R 2-5 are independently halogen, hydroxyl, —N(R 2-4-1 )(R 2-4-2 ) or C 1 -C 6 alkoxy; R 2-4-1 and R 2-4-2 are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl, or, phenyl substituted by one or more R 2-2-1 ; R 2-2-1 is independently halogen;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

R 2-6-1-1 is independently halogen;

R 2-6-1-2 , R 2-6-1-3 and R 2-6-1-4 are independently C 1 -C 6 alkyl;

R 2-7 is C 1 -C 6 alkyl;

R 2-8 and R 2-9 are independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, or C 6 -C 10 aryl substituted by one or more R 2-8-1 ;

R 2-8-1 is halogen or C 1 -C 6 alkoxy;

R 2-10 is independently C 1 -C 6 alkyl or oxo;

R 2-11 , R 2-12 , R 2-13 , R 2-14 , R 2-15 , R 2-16 , R 2-17 , R 2-18 , R 2-19 , R 2-20 , R 2-21 , R 2-22 , R 2-23 , R 2-24 and R 2-25 are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-11-1 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, or “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-11-2 ;

R 2-11-1 and R 2-11-2 are independently halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy or C 3 -C 6 cycloalkyl;

R 2 is located on

3 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 2 , wherein,

when R 1-1 is C 1 -C 6 alkyl, the C 1 -C 6 alkyl is C 1 -C 4 alkyl;

or, when R 3-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2 is halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2 is C 1 -C 10 alkyl, the C 1 -C 10 alkyl is C 1 -C 4 alkyl;

or, when R 2 is C 1 -C 10 alkyl substituted by one or more R 2-1 , the C 1 -C 10 alkyl is C 1 -C 4 alkyl;

or, when R 2 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2 is “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heterocycloalkyl, the heteroatoms are selected from one or more of N and O;

or, when R 2 is “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heteroaryl, the heteroatoms are N;

or, when R 2 is “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 , in the 5- to 6-membered heterocycloalkyl, the heteroatoms are N;

or, when R 2-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-6 is C 1 -C 10 alkyl, the C 1 -C 10 alkyl is C 1 -C 6 alkyl;

or, when R 2-6 is C 1 -C 10 alkyl substituted by one or more R 2-6-1 , the C 1 -C 10 alkyl is C 1 -C 4 alkyl;

or, when R 2-6 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2-6 is C 6 -C 10 aryl, the C 6 -C 10 aryl is phenyl or naphthyl;

or, when R 2-6 is C 6 -C 10 aryl substituted by one or more R 2-6-2 , the C 6 -C 10 aryl is phenyl or naphthyl;

or, when R 2-6 is “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-6-3 , the 3- to 6-membered heterocycloalkyl is 3- to 4-membered heterocycloalkyl;

or, when R 2-6-1 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-6-1 is independently C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is C 1 -C 4 alkoxy;

or, when R 2-6-1 is independently C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2-6-1 is independently C 6 -C 10 aryl, the C 6 -C 10 aryl is phenyl or naphthyl;

or, when R 2-6-1 is independently C 6 -Clo aryl substituted by one or more R 2-6-1-1 , the C 6 -C 10 aryl is phenyl or naphthyl;

or, when R 2-6-2 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-6-2 is independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is C 1 -C 4 alkyl;

or, when R 2-6-2 is independently C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is C 1 -C 4 alkoxy;

or, when R 2-6-3 is independently —C(═O)—C 1 -C 4 alkyl, in the —C(═O)—C 1 -C 4 alkyl, the C 1 -C 4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, R 2-6-1-1 is independently fluorine, chlorine, bromine or iodine;

or, R 2-7 is C 1 -C 4 alkyl;

or, when R 2-8 and R 2-9 are independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is C 1 -C 4 alkyl;

or, when R 2-8 and R 2-9 are independently C 6 -C 10 aryl, the C 6 -C 10 aryl is phenyl or naphthyl;

or, when R 2-8 and R 2-9 are independently C 6 -C 10 aryl substituted by one or more R 2-8-1 , in the C 6 -C 10 aryl substituted by one or more R 2-8-1 , the C 6 -C 10 aryl is phenyl or naphthyl;

or, when R 2-8-1 is halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-8-1 is C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is C 1 -C 4 alkoxy;

or, when R 2-10 is independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is C 1 -C 4 alkyl;

or, when R 1-1 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl;

or, when R 1-1 is C 1 -C 6 alky substituted by one or more R 1-1-1 , in the C 1 -C 6 alky substituted by one or more R 1-1-1 , the C 1 -C 6 alkyl is C 1 -C 4 alkyl;

or, when R 1-1 is C 3 -C 6 cycloalkyl substituted by one or more R 1-1-2 , in the C 3 -C 6 cycloalkyl substituted by one or more R 1-1-2 , the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl;

or, when R 1-1-1 and R 1-1-2 are independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 3-1 is independently C 1 -C 6 alkoxy or C 1 -C 6 alkoxy substituted by one or more R 3-1-2 , in the C 1 -C 6 alkoxy or C 1 -C 6 alkoxy substituted by one or more R 3-1-2 , the C 1 -C 6 alkoxy is C 1 -C 4 alkoxy;

or, when R 3-1-1 and R 3-1-2 are independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2 is C 2 -C 10 alkenyl, C 2 -C 10 alkenyl substituted by one or more R 2-26 , in the C 2 -C 10 alkenyl and C 2 -C 10 alkenyl substituted by one or more R 2-26 , the C 2 -C 10 alkenyl is C 2 -C 4 alkenyl;

or, when R 2 is C 2 -C 10 alkynyl or C 2 -C 10 alkynyl substituted by one or more R 2-27 , in the C 2 -C 10 alkynyl and C 2 -C 10 alkynyl substituted by one or more R 2-27 , the C 2 -C 10 alkynyl is C 2 -C 4 alkynyl;

or, when R 2-26 and R 2-27 are independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2 is “3- to 4-membered heterocycloalkyl with 1 or 2 heteroatoms selected from one or more of N, O and S” or “3- to 4-membered heterocycloalkyl with 1 or 2 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 , in the 3- to 4-membered heterocycloalkyl, the heteroatoms are selected from one or more of N and O;

or, when R 2 is “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-5 , in the 5- to 6-membered heteroaryl, the heteroatoms are N;

or, when R 2-1 is independently C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2-2 is C 1 -C 6 alkyl or C 1 -C 6 alkyl substituted by one or more R 2-2-2 , the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or isopentyl or, when R 2-2 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2-2-2 is independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-4 and R 2-5 are independently halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-4 and R 2-5 are independently C 1 -C 6 alkyl or C 1 -C 6 alkyl substituted by one or more R 2-4-3 , in the C 1 -C 6 alkyl and C 1 -C 6 alkyl substituted by one or more R 2-4-3 , the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or isopentyl;

or, when R 2-4-3 is halogen, the halogen is fluorine, chlorine, bromine or iodine;

or, when R 2-7 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

or, when R 2 is “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the 5- to 6-membered heterocycloalkyl is

4 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 2 , wherein,

is a double bond;

or, R 1 is

or, R 1-1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyl substituted by one or more R 1-1-1 or C 3 -C 6 cycloalkyl substituted by one or more R 1-1-2 ;

or, R 3 is

or, n is 1, 2 or 3;

or, R 3-1 is independently halogen, cyano, hydroxyl, C 1 -C 6 alkoxy substituted by one or more R 3-1-2 ;

or, m is 0 or 1;

or, R 2 is oxo, halogen, cyano, isocyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 2 -C 10 alkenyl, C 2 -C 10 alkenyl substituted by one or more R 2-26 , C 2 -C 10 alkynyl, C 2 -C 10 alkynyl substituted by one or more R 2-27 , C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “3- to 4-membered heterocycloalkyl with 1 or 2 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-4 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-5 , —(C═O)—R 2-2 , —OR 2-6 , —C(═O)OR 2-7 , —NR 2-8 R 2-9 , or, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 ;

or, R 2 is oxo, halogen, cyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 3 -C 6 cycloalkyl, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, or, —OR 2-6 ;

or, R 2-6 is hydrogen, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-6-1 , C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, C 6 -C 10 aryl substituted by one or more R 2-6-2 , “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” or, “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-6-3 ;

or, R 2-6-1 is independently halogen, hydroxyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, or, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ;

or, R 1-1 is C 1 -C 6 alkyl;

or, R 1-1-1 and R 1-1-2 are independently halogen;

or, R 2-1 is independently halogen, C 3 -C 6 cycloalkyl or phenyl;

or, R 2-1 is independently halogen;

or, R 2-2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl, C 1 -C 6 alkyl substituted by one or more R 2-2-2 ;

or, R 2-4 and R 2-5 are independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more R 2-4-3 ;

or, R 2-7 is C 3 -C 6 cycloalkyl or phenyl.

5 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 1 , wherein,

when R 3 is

the R 3 is

or, when R 3 is

the R 3 is

or, when R 3 is

the R 3 is

or, R 2 is oxo, methoxy, fluorine, chlorine, hydroxyl, amino, —CH 2 F, difluoromethyl, trifluoromethyl, methyl, isopropyl, cyclopropyl, cyano, ethoxy, isopropoxy, monofluoromethoxy, difluoromethoxy, trifluoromethoxy,

or, R 2 is oxo, methoxy, fluorine, chlorine, hydroxyl, amino, difluoromethyl, trifluoromethyl, isopropyl, cyclopropyl, cyano, ethoxy, isopropoxy, difluoromethoxy,

a end represents the position connected to Z 10 .

6 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 1 , wherein, the compound is any of the following schemes:

scheme 1:

is a double bond;

is benzene ring, 6-membered heteroaromatic ring having one or two heteroatoms N or 6-membered heterocycloalkene having one heteroatom N;

is benzene ring;

R 1 is

R 1-1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyl substituted by one or more R 1-1-1 or C 3 -C 6 cycloalkyl substituted by one or more R 1-1-2 ;

R 1-1-1 and R 1-1-2 are independently halogen;

R 3 is

n is 1, 2 or 3;

R 3-1 is independently halogen, cyano or hydroxyl;

m is 0, 1;

R 2 is oxo, halogen, cyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, —OR 2-6 , —C(═O)OR 2-7 , —NR 2-8 R 2-9 , or, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 ;

R 2-1 is independently halogen;

R 2-6-1 is independently halogen, hydroxyl, C 3 -C 6 cycloalkyl, or, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

R 2-6-1-1 is independently halogen;

R 2-7 is C 1 -C 6 alkyl;

R 2-8 and R 2-9 are independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, or C 6 -C 10 aryl substituted by one or more R 2-8-1 ;

R 2-8-1 is halogen or C 1 -C 6 alkoxy;

R 2-10 is independently C 1 -C 6 alkyl or oxo;

scheme 2:

is a double bond;

is benzene ring, 6-membered heteroaromatic ring having one or two heteroatoms N or 6-membered heterocycloalkene having one heteroatom N;

is benzene ring;

R 1 is

R 3 is

n is 1, 2 or 3;

R 3-1 is independently halogen, cyano or hydroxyl;

m is 0 or 1;

R 2 is oxo, halogen, cyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 C 3 -C 6 cycloalkyl, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S, or, —OR 2-6 ;

R 2-1 is independently halogen;

R 2-6-1 is independently halogen, C 3 -C 6 cycloalkyl, or, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ; R 2-6-1-1 is independently halogen;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

R 2-6-1-1 is independently halogen;

R 2-10 is independently C 1 -C 6 alkyl or oxo;

scheme 3:

is benzene ring, or 6-membered heteroaromatic ring having one or two heteroatoms N;

is benzene ring;

R 1 is

R 3 is

n is 1, 2 or 3;

R 3-1 is independently halogen, cyano or hydroxyl;

m is 0 or 1;

R 2 is oxo, halogen, cyano, C 1 -C 10 alkyl or C 1 -C 10 alkyl substituted by one or more R 2-1 , C 3 -C 6 cycloalkyl, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, or, —OR 2-6 ;

R 2-1 is independently halogen;

R 2-6 is C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-6-1 , C 3 -C 6 cycloalkyl, C 6 -C 10 aryl substituted by one or more R 2-6-2 , “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” or, “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-6-3 ;

R 2-6-1 is independently halogen, C 3 -C 6 cycloalkyl, or, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ; R 2-6-1-1 is independently halogen;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

scheme 4:

is benzene ring, or 6-membered heteroaromatic ring having one heteroatom N;

is benzene ring;

R 1 is

R 3 is

n is 1, 2 or 3;

R 3-1 is independently halogen, cyano or hydroxyl;

m is 0 or 1;

R 2 is chlorine, cyano, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 3 -C 6 cycloalkyl, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, or, —OR 2-6 ;

R 2-1 is independently halogen;

R 26 is C 1 -C 4 alkyl, C 1 -C 2 alkyl substituted by one or more R 2-6-1 , C 3 -C 6 cycloalkyl, C 6 -C 10 aryl substituted by one or more R 2-6-2 , “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” or, “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-6-3 ; and when R 2 is chlorine, R 2 is located on Z 1 or Z 4 ;

R 2-6-1 is independently halogen, C 3 -C 6 cycloalkyl, or, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

scheme 5:

wherein,

is a double bond;

is benzene ring, 6-membered heteroaromatic ring having one or two heteroatoms N or 6-membered heterocycloalkene having one heteroatom N;

is benzene ring;

R 1 is

R 1-1 is C 1 -C 6 alkyl;

R 3 is

n is 1, 2 or 3;

R 3-1 is independently halogen, cyano, hydroxyl, or, C 1 -C 6 alkoxy substituted by one or more R 3-1-2 ;

m is 0 or 1;

R 2 is oxo, halogen, cyano, amino, isocyano, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 2 -C 10 alkenyl, C 2 -C 10 alkenyl substituted by one or more R 2-26 , C 2 -C 10 alkynyl, C 2 -C 10 alkynyl substituted by one or more R 2-27 , C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “3- to 4-membered heterocycloalkyl with 1 or 2 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-4 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-5 , —(C═O)-R 2-2 , —OR 2-6 , —C(═O)OR 2-7 , —NR 2-8 R 2-9 , or, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 ;

R 2-1 is independently halogen, C 3 -C 6 cycloalkyl or phenyl;

R 2-2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl, or, C 1 -C 6 alkyl substituted by one or more R 2-2-2 ; R 2-2-2 is independently halogen;

R 2-4 and R 2-5 are independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more R 2-4-3 ; R 2-4-3 is halogen;

R 2-6-1 is independently halogen, hydroxyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, or, C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

R 2-6-1-1 is independently halogen;

R 2-6-1-2 is independently C 1 -C 6 alkyl;

R 2-7 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or phenyl;

R 2-8 and R 2-9 are independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, or C 6 -C 10 aryl substituted by one or more R 2-8-1 ;

R 2-8-1 is halogen or C 1 -C 6 alkoxy;

R 2-10 is independently C 1 -C 6 alkyl or oxo;

R 2-26 and R 2-27 are independently halogen or C 1 -C 6 alkyl;

scheme 6:

the compound represented by formula I is any of the following compound:

or, scheme 7:

the pharmaceutically acceptable salt of the compound represented by formula I is the following compound:

trifluoroacetate of

7 . A preparation method of the compound represented by formula I as defined in claim 1 , wherein, the method is any of the following schemes:

scheme 1: in solvent, under the action of a base, a compound represented by formula II is subjected to the following reaction to obtain the compound represented by formula I,

wherein, the base can e sodium ethoxide, ammonia or water hydrazine;

scheme 2: in solvent, a compound represented by formula III and ammonia are subjected to the following reaction to obtain the compound represented by formula I,

or, scheme 3: in solvent, under the action of trifluoroacetic acid, a compound represented by formula IV is subjected to the following reaction to obtain the compound represented by formula I,

8 . A compound represented by formula II, III or IV,

wherein,

is a single bond or a double bond;

is benzene ring, 6-membered heteroaromatic ring having one or two heteroatoms N or 6-membered heterocycloalkene having one heteroatom N;

is benzene ring;

R 3 is

n is 0, 1, 2 or 3;

R 3-1 is independently halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyl substituted by one or more R 3-1 , C 1 -C 6 alkoxy substituted by one or more R 3-1-2 , or C 1 -C 6 alkoxy substituted by C 1 -C 6 alkoxy; R 3-1-1 and R 3-1-2 are independently halogen;

R 3-2-1 , R 3-2-2 and R 3-2-3 are independently halogen, hydroxyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, or, C 1 -C 6 alkoxy substituted by C 1 -C 6 alkoxy;

m is 0, 1, 2, 3 or 4;

R 2-1 is independently halogen, hydroxyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl substituted by one or more R 2-1-8 , “4- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “4- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-1-7 , phenyl, phenyl substituted by one or more R 2-1-1 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-1-6 , —OR 2-1-2 , —N(R 2-1-3 )(R 2-1-4 ), or, —S(═O) 2 R 2-1-5 ;

R 2-1 , R 2-1-6 , R 2-1-7 and R 2-1-8 are independently oxo, hydroxyl, amino, carboxyl, halogen, —CN, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted by one or more halogen, —OR 2-1-1 , or, —N(R 2-1-1-2 )(R 2-1-1-3 ); R 2-1-1 , R 2-1-1-2 and R 2-1-1-3 are independently C 1 -C 6 alkyl;

R 2-1-2 is independently C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-1-3 and R 2-1-4 are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-1-5 is independently C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 2-3 is independently C 1 -C 6 alkyl;

R 2-2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl, C 1 -C 6 alkyl substituted by one or more R 2-2-2 , or, phenyl substituted by one or more R 2-2-1 ; R 2-2-1 is independently halogen; R 2-2-2 is independently halogen;

R 2-6-2 is independently halogen, C 1 -C 6 alkyl or C 1 -C 6 alkoxy;

R 2-6-3 is independently —C(═O)—C 1 -C 6 alkyl;

R 2-6-1-1 is independently halogen;

R 2-6-1-2 , R 2-6-1-3 and R 2-6-1-4 are independently C 1 -C 6 alkyl;

R 2-7 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or phenyl;

R 2-8 and R 2-9 are independently hydrogen, C 1 -C 6 alkyl, C 6 -C 10 aryl, or C 6 -C 10 aryl substituted by one or more R 2-8-1 ;

R 2-8-1 is halogen or C 1 -C 6 alkoxy;

R 2-10 is independently C 1 -C 6 alkyl or oxo;

R 2-26 and R 2-27 are independently halogen or C 1 -C 6 alkyl;

R 2-11 , R 2-12 , R 2-13 , R 2-14 , R 2-1 , R 2-16 , R 2-17 , R 2-18 , R 2-19 , R 2-20 , R 2-21 , R 2-22 , R 2-23 , R 2-24 and R 2-2 are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, phenyl, phenyl substituted by one or more R 2-11-1 , “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, or “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-1-2 ;

R 2-11-1 and R 2-11-2 are independently halogen, cyano, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy or C 3 -C 6 cycloalkyl;

R 2 is located on

9 . The compound represented by formula II, III or IV as claimed in claim 8 , wherein,

the compound represented by formula II is

the compound represented by formula III is

the compound represented by formula IV is

10 . A compound represented by the following formula, and the compound is selected form,

11 . A pharmaceutical composition, comprising substance A and at least one of pharmaceutical excipients;

the substance A is the fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as defined in claim 1 .

12 . A method for treating disease comprising administering a therapeutically effective amount of substance A to a patient;

the diseases is urinary tract disease, respiratory disease, pain, inflammation, arthritis, myocardial infarction, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, gastric bowel dysfunction, or endometriosis;

the urinary tract disease is urinary incontinence, or cystitis;

the respiratory diseases are breathing disorder comprising chronic obstructive pulmonary disease, asthma, or cough.

13 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 3 , wherein,

when R 1-1 is C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 3-1 is independently halogen, the halogen is fluorine or chlorine;

or, when R 2 is halogen, the halogen is fluorine or chlorine;

or, when R 2 is C 1 -C 10 alkyl, the C 1 -C 10 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2 is C 1 -C 10 alkyl substituted by one or more R 2-1 , the C 1 -C 10 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl or cyclobutyl;

or, when R 2 is “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heterocycloalkyl, the heteroatom number is 1 or 2;

or, when R 2 is “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heteroaryl, the heteroatom number is 2;

or, when R 2-1 is independently halogen, the halogen is fluorine;

or, when R 2-6 is C 1 -C 10 alkyl, the C 1 -C 10 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl tert-butyl, n-pentyl, isopentyl or n-butyl;

or, when R 2-6 is C 1 -C 10 alkyl substituted by one or more R 2-6-1 , the C 1 -C 10 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2-6 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl;

or, when R 2-6 is C 6 -C 10 aryl substituted by one or more R 2-6-2 , the C 6 -C 10 aryl is phenyl;

or, when R 2-6 is “3- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, the 3- to 6-membered heterocycloalkyl is 3- to 4-membered heterocycloalkyl; in the 3- to 4-membered heterocycloalkyl, the heteroatoms is N;

or, when R 2-6-1 is independently fluorine;

or, when R 2-6-1 is independently C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;

or, when R 2-6-1 is independently C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl;

or, when R 2-6-1 is independently C 6 -C 10 aryl substituted by one or more R 2-6-1-1 , the C 6 -C 10 aryl is phenyl;

or, when R 2-6-2 is independently halogen, the halogen is fluorine;

or, when R 2-6-2 is independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2-6-2 is independently C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;

or, when R 2-6-3 is independently —C(═O)—C 1 -C 4 alkyl, in the —C(═O)—C 1 -C 4 alkyl, the C 1 -C 4 alkyl is methyl;

or, R 2-6-1-1 is independently fluorine;

or, R 2-7 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2-8 and R 2-9 are independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 2-8 and R 2-9 are independently C 6 -C 10 aryl substituted by one or more R 2-8-1 , in the C 6 -C 10 aryl substituted by one or more R 2-8-1 , the C 6 -C 10 aryl is phenyl;

or, when R 2-8-1 is halogen, the halogen is fluorine;

or, when R 2-8-1 is C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;

or, when R 2-10 is independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 1-1 is C 1 -C 6 alky substituted by one or more R 1-1-1 , in the C 1 -C 6 alky substituted by one or more R 1-1-1 , the C 1 -C 6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl;

or, when R 3-1-1 and R 3-1-2 are independently halogen, the halogen is fluorine or chlorine;

or, when R 2 is C 2 -C 10 alkenyl, C 2 -C 10 alkenyl substituted by one or more R 2-26 , in the C 2 -C 10 alkenyl and C 2 -C 10 alkenyl substituted by one or more R 2-26 , the C 2 -C 10 alkenyl is vinyl or allyl;

or, when R 2 is C 2 -C 10 alkynyl or C 2 -C 10 alkynyl substituted by one or more R 2-27 , in the C 2 -C 10 alkynyl and C 2 -C 10 alkynyl substituted by one or more R 2-27 , the C 2 -C 10 alkynyl is ethynyl and propynyl;

or, when R 2-26 and R 2-27 are independently halogen, the halogen is fluorine or chlorine;

or, when R 2-1 is independently C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl or cyclobutyl;

or, when R 2-2 is C 1 -C 6 alkyl or C 1 -C 6 alkyl substituted by one or more R 2-2-2 , the C 1 -C 6 alkyl is methyl;

or, when R 2-2 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl or cyclobutyl;

or, when R 2-2-2 is independently halogen, the halogen is fluorine or chlorine;

or, when R 2-4 and R 2-5 are independently fluorine or chlorine;

or, when R 2-4-3 is halogen, the halogen is fluorine or chlorine;

or, when R 2-7 is C 3 -C 6 cycloalkyl, the C 3 -C 6 cycloalkyl is cyclopropyl.

14 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 13 , wherein,

in the 6-membered heterocycloalkene,

is a double bond;

or, when R 1-1 is C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl;

or, when R 2 is C 1 -C 10 alkyl, the C 1 -C 10 alkyl is methyl or isopropyl;

or, when R 2 is C 1 -C 10 alkyl substituted by one or more R 2-1 , the C 1 -C 10 alkyl is methyl;

or, when R 2 is “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heterocycloalkyl, the 5- to 6-membered heterocycloalkyl is

or, when R 2 is “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl is

or, when R 2-6 is C 1 -C 10 alkyl, the C 1 -C 10 alkyl is methyl, ethyl, isobutyl or isopentyl;

or, when R 2-6 is C 1 -C 10 alkyl substituted by one or more R 2-6-1 , the C 1 -C 10 alkyl is methyl or ethyl;

or, when R 2-6-1 is independently C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is methoxy;

or, when R 2-6-2 is independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl;

or, when R 2-6-2 is independently C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is methoxy;

or, R 2-7 is methyl;

or, when R 2-8 and R 2-9 are independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is isopropyl;

or, when R 2-8-1 is C 1 -C 6 alkoxy, the C 1 -C 6 alkoxy is methoxy;

or, when R 2-10 is independently C 1 -C 6 alkyl, the C 1 -C 6 alkyl is methyl;

or, when R 2 is “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-5 , in the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl is

15 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 14 , wherein,

when R 2 is “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, in the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl is

16 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 4 , wherein,

R 3-1 is independently halogen, cyano or hydroxyl;

or, R 2 is oxo, halogen, cyano, amino, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted by one or more R 2-1 , C 3 -C 6 cycloalkyl, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, “5- to 6-membered heteroaryl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S”, —OR 2-6 , —C(═O)OR 2-7 , —NR 2-8 R 2-9 , or, “5- to 6-membered heterocycloalkyl with 1, 2 or 3 heteroatoms selected from one or more of N, O and S” substituted by one or more R 2-10 ;

or, R 2-6-1 is independently halogen, C 3 -C 6 cycloalkyl or C 6 -C 10 aryl substituted by one or more R 2-6-1-1 ;

or, R 2-1 is independently halogen.

17 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 5 , wherein,

when R 3 is

the R 3 is

or, when R 3 is

the R 3 is

or, when R 3 is

the R 3 is

18 . The method as claimed in claim 12 , wherein,

the pain is inflammatory pain, surgical pain, visceral pain, toothache, premenstrual pain, central pain, pain caused by burns, migraine, cluster headache or chronic pain;

or, the animal is human;

or, the bronchospasm or cough is chronic cough.

19 . The fused ring compound represented by formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, the isotopic compound thereof, the crystal form thereof, the nitrogen oxide thereof, the solvate thereof or the solvate of the pharmaceutically acceptable salt thereof as claimed in claim 1 , wherein,

is 6-membered heterocycloalkene having one heteroatom N.